April 23, 2024


Bristol-Myers Squibb Firm (NYSE:BMY) is a high-quality, top-notch biopharma firm that has been battered over the previous yr. Based mostly on its whole return of -28% over the previous yr, it’s means beneath its 5Y and 10Y whole return CAGR of three.4% and a couple of.2%, respectively. In differentSPXSPY